ZYDUSLIFE — Zydus Lifesciences Share Price
0.000.00%
Last trade - 00:00- IN₹892.08bn
- IN₹887.33bn
- IN₹195.47bn
- 97
- 23
- 68
- 71
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 18.67 | ||
| PEG Ratio (f) | 104.84 | ||
| EPS Growth (f) | 0.18% | ||
| Dividend Yield (f) | 0.74% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.96 | ||
| Price to Tang. Book | 6.35 | ||
| Price to Free Cashflow | 27.16 | ||
| Price to Sales | 3.89 | ||
| EV to EBITDA | 13.54 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 20.97% | ||
| Return on Equity | 22.36% | ||
| Operating Margin | 24.6% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 142,531 | 144,035 | 151,099 | 172,374 | 195,474 | 229,503.61 | 244,620.66 | 8.23% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -20.52 | +62.36 | -10.15 | +13.23 | +59.41 | +21.16 | +0.23 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
Directors
- Pankaj Patel NEC (68)
- Nitin Parekh CFO
- Ganesh Nayak COO (66)
- Dhaval Soni CCO
- Sharvil Patel MDR (42)
- Mukesh Patel NED (67)
- Nitin Desai NID
- Apurva Diwanji NID (52)
- Dharmishtaben Raval NID (64)
- Bhadresh Shah NID (69)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 15th, 1995
- Public Since
- May 15th, 1995
- No. of Shareholders
- 300,331
- No. of Employees
- 26,240
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 1,006,233,990
- Address
- Zydue Tower, Satellite Cross Road, AHMEDABAD, 382481
- Web
- https://www.zyduslife.com/zyduslife/
- Phone
- +91 7926868100
- Contact
- Arvind Bothra
- Auditors
- Deloitte Haskins & Sells LLP
Upcoming Events for ZYDUSLIFE
Zydus Lifesciences Ltd Annual Shareholders Meeting
Similar to ZYDUSLIFE
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Zydus Lifesciences share price?
As of Today at 24:17 UTC, shares in Zydus Lifesciences are trading at IN₹859.65. This share price information is delayed by 15 minutes.
How has the Zydus Lifesciences share price performed this year?
Shares in Zydus Lifesciences last closed at IN₹859.65 and the price had moved by -9.63% over the past 365 days. In terms of relative price strength the Zydus Lifesciences share price has underperformed the S&P BSE 100 Index by -14.87% over the past year.
What are the analyst and broker recommendations for Zydus Lifesciences?
The overall consensus recommendation for Zydus Lifesciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Zydus Lifesciences dividend yield?
The Zydus Lifesciences dividend yield is 0.35% based on the trailing twelve month period.
Does Zydus Lifesciences pay a dividend?
Last year, Zydus Lifesciences paid a total dividend of IN₹3.00, and it currently has a trailing dividend yield of 0.35%. We do not have any data on when Zydus Lifesciences is to next pay dividends.
When does Zydus Lifesciences next pay dividends?
We do not have data on when Zydus Lifesciences is to next pay dividends. The historic dividend yield on Zydus Lifesciences shares is currently 0.35%.
How do I buy Zydus Lifesciences shares?
To buy shares in Zydus Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Zydus Lifesciences?
As of the previous close price of IN₹859.65, shares in Zydus Lifesciences had a market capitalisation of IN₹892.08bn.
Where are Zydus Lifesciences shares listed?
Here are the trading details for Zydus Lifesciences:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: ZYDUSLIFE
What kind of share is Zydus Lifesciences?
Based on an overall assessment of its quality, value and momentum Zydus Lifesciences is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Zydus Lifesciences share price forecast for 2025?
The analyst consensus target price for shares in Zydus Lifesciences is IN₹1,008.65. That is 17.33% above the last closing price of IN₹859.65.
Analysts covering Zydus Lifesciences currently have a consensus Earnings Per Share (EPS) forecast of IN₹45.96 for the next financial year.
Find out moreWhat is the trend in the Zydus Lifesciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zydus Lifesciences. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -11.38%.
As of the last closing price of IN₹859.65, shares in Zydus Lifesciences were trading -15.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Zydus Lifesciences PE Ratio?
The Zydus Lifesciences PE ratio based on its reported earnings over the past 12 months is 18.67. The shares last closed at IN₹859.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Zydus Lifesciences?
Zydus Lifesciences' management team is headed by:
- Pankaj Patel - NEC
- Nitin Parekh - CFO
- Ganesh Nayak - COO
- Dhaval Soni - CCO
- Sharvil Patel - MDR
- Mukesh Patel - NED
- Nitin Desai - NID
- Apurva Diwanji - NID
- Dharmishtaben Raval - NID
- Bhadresh Shah - NID